IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
Australia ASIC Tightens Auditor Oversight After KPMG Leak Scandal 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
Elon Musk Fuels SpaceX-Tesla Merger Speculation After Earnings Call 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
